Address of Corresponding Author

Med Princ Pract 2006;15:266-269 (DOI: 10.1159/000092988)

  Key Words

• Hepatitis A virus
• Hepatitis A vaccine
• Kuwait

  Abstract

Objective: To describe the epidemiology, clinical features and outcome of hepatitis A virus (HAV) infection in children in Kuwait. Subjects and Method: The medical records of 350 patients (age 0-16 years) admitted to the Infectious Diseases Hospital, Kuwait, between January 2000 and December 2002, with hepatitis A infection were reviewed. Results: The mean age was 8.6 ± 3.8 years and 47% of patients were between 7 and 12 years old. Kuwaiti children comprised 44% of admitted patients. The largest proportion of children with hepatitis A (34%) were from the northern part of the country. HAV infection was prevalent throughout the year with a peak during the months of August to October. Of the Kuwaiti children, 31% reported a history of contact with jaundiced patients, while 52% of the non-Kuwaiti children had a history of recent travel prior to their illness. Patients had symptoms for a mean of 6 ± 3.6 days prior to presentation. The mean length of hospitalization was 5.8 ± 2.9 days. The rate of complications of HAV infection was 6% and only one child required admission to the intensive care unit for fulminant hepatitis. None of the patients had permanent sequelae. Conclusions: HAV infection is a significant cause of morbidity for children in Kuwait. The disease is mostly prevalent in preschool and school age children. Despite the excellent outcome of all patients, a considerable number of patients tend to have a complicated course and prolonged hospitalization. In view of these data, hepatitis A vaccine should be considered as a part of routine childhood immunization in Kuwait.

Copyright © 2006 S. Karger AG, Basel

  References

1.

Alter MJ, Gallagher M, Morris TT, Moyer LA, Meeks EL, Krawczynski K, Kim JP, Margolis HS: Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med 1997;336:741-746.

2.

Craig AS, Schaffner W: Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med 2004;350:476-481.

3.

Kemmer NM, Miskovsky EP: Infections of the liver; hepatitis A. Infect Dis Clin North Am 2000;14:605-615.

4.

Ciccozzi M, Tosti ME, Gallo G, Ragni P, Zotti C, Lopalco P, Ara G, Sangalli M, Balocchini E, Szklo AS, Mele A, SEIEVA collaborating group: Risk of hepatitis A infection following travel. J Viral Hepat 2002;9:460-465.

5.

Tufenkeji H: Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine 2000;18:S65-S67.

6.

Ministry of Health, Kuwait. Vital Statistics Book, 2002.

7.

Fathalla SE, Al-Jama AA, Al-Sheikh IH, Islam SI: Seroprevalence of hepatitis A virus in Eastern Saudi Arabia. Saudi Med J 2000;21:945-948.

8.

Nordenfelt E, Atack W, Al-Kandari, Al-Nakib W: Hepatitis A in Kuwait. J Kuwait Med Assoc 1985;19:103-108.

9.

Kang JH, Lee KY, Kim CH, Sim D: Changing hepatitis A epidemiology and the need for vaccination in Korea. Asian Pac J Allergy Immunol 2004;22:237-242.

10.

Staes CJ, Schlenker TL, Risk I, Cannon KG, Harris H, Pavia AT, Shapiro CN, Bell BP: Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 2000;106:E54.

11.

Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, Fleenor M, Ryder PL, Margolis HS: The diverse patterns of hepatitis A epidemiology in the United States: implications for vaccination strategies. J Infect Dis 1998;178:1579-1584.

12.

Meyerhoff AS, Jacobs RJ: Transmission of hepatitis A through household contact. J Viral Hepat 2001;8:454-458.

13.

Weinberg M, Waterman S, Lucas CA, Falcon VC, Morales PK, Lopez LA, Peter C, Gutierrez AE, Gonzalez ER, Flisser A, Bryan R, Valle EN, Rodriguez A, Hernandez GA, Rosales C, Ortiz JA, Landen M, Vilchis H, Rawlings J, Leal FL, Ortega L, Flagg E, Conyer RT, Cetron M: The US-Mexico Border Infectious Disease Surveillance project: establishing bi-national border surveillance. Emerg Infect Dis 2003;9:97-102.

14.

Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1-37.

15.

Wiedermann G, Kundi M, Ambrosch F: Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop 1998;69:121-125.

  Author Contacts

Dr. Entesar Husain
Department of Pediatrics, Al-Amiri Hospital
PO Box 4077
13041 Safat (Kuwait)
Tel./Fax +965 543 0207, E-Mail entesar@qualitynet.net

  Article Information

This paper was presented in part at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, Calif., USA, October 9-12, 2003 (abstract No. 582).

Received: July 17, 2005
Revised: October 25, 2005
Number of Print Pages : 4
Number of Figures : 3, Number of Tables : 0, Number of References : 15

  Publication Details

Medical Principles and Practice (International Journal of the Kuwait University Health Sciences Centre)

Vol. 15, No. 4, Year 2006 (Cover Date: June 2006)

Journal Editor: Al-Zaid, N.S. (Kuwait)
ISSN: 1011-7571 (print), 1423-0151 (Online)

For additional information: http://www.karger.com/MPP

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.